Asociación entre adiponectina y el síndrome de ovario poliquístico. Revisión de la literatura

Carlos Bustamante-Zuluaga, Felipe Vergara-Quintero, Israel Díaz-Yunez

Resumen


Objetivo: evaluar la literatura existente respecto a la asociación entre la adiponectina y el síndrome de ovario poliquístico (SOP).

Materiales y métodos: se realizó una búsqueda bibliográfica en las bases de datos electrónicas Scielo, lilacs, PubMed vía ovid, así como de revistas indexadas y sociedades médicas reconocidas tales comoFertility and SterilityThe European Journal of EndocrinologyThe Journal of Biological ChemistryHuman Reproduction y Nature Medicine.

Resultados: se revisaron 75 títulos, de los cuales 50 cumplían con nuestros criterios de selección, correspondientes a diseños de tipo transversal, casos y controles, y un metaanálisis. Los niveles de adiponectina sérica fueron menores en mujeres con síndrome de ovario poliquístico. Los resultados respecto a los niveles de adiponectina y la obesidad son contradictorios en mujeres con y sin SOP. Es escasa la información respecto a esta asociación en la población latinoamericana.

Conclusión: la literatura muestra que hay una asociación entre los niveles bajos de adiponectina y las mujeres que presentan síndrome de ovario poliquístico, independientemente de la presencia o no de obesidad.


Palabras clave


Adiponectin; obesity; hyperandrogenism; insulin resistance; polycystic ovary syndrome

Texto completo:

PDF

Referencias


Chang RJ. A practical approach to the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol. 2004;191:713-17.

Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowickz DJ, Nestler JE. A modern medical quandary: Polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab. 2003;88:1927-32.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.

Azziz R. Diagnosis of polycystic ovary syndrome: The Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006;91:781-85.

Olutunmbi Y, Paley K, English JC III. Adolescent female acne: etiology and management. J Pediatr Adolesc Gynecol. 2008;21:171-76.

Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus WorkshopGroup. Fertil Steril. 2012;97: 28-38.e25.

National Institute of Health (NIH). Evidencebased Methodology Workshop on Polycystic Ovary Syndrome. December 3-5, 2012.

Poretsky L, Piper B. Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynecol. 1994;84:613-21.

Speroff L, Fritz MA. Anovulation and the Polycystic Ovary, Insulin Resistance, Hyperinsulinemia, and Hyperandrogenism. En: Speroff L, Fritz M. Clinical Gynecologic Endocrinology and Infertility. 7 Edition; 2005. p. 476-83.

Poretsky L. Insulin resistance and hyperandrogenism: Update. Endoc Rev 1994;2:26-35.

Taylor AE. Polycystic ovary syndrome. Endoc Metab Clin North Am. 1998;27:877-902.

Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell Press. 2004;116:337-50.

Hotamisligil GS. The role of TNFaand TNF receptors in obesity and insulin resistance. J Intern Med. 1999; 245: 612-25.

Ailhaud G, Grimaldi P, Négrel R. Adipose cell diferentiation: a long way to Tipperary. Centre Biochimie, Parc Valrose, 06108 Nice cédex 2, France.

Wong GW, Wang J, Hug C, Tsao S, Lodish HF. A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci. 2004;101:10302-7.

Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care. 2003;26:30-5.

Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose- specific gene dysregulated in obesity. J Biol Chem. 1996;271:10697-703.

Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem. 1996;120:803-12.

Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221:286-9.

Tsao TS, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, Heuser JE, Lodish HF. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem. 2003;278:50810-17.

Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocrine Reviews. 2005;26:439-51.

Elissondo N, Gómez Rosso L, Maidana P, Brites F. Adiponectina: una adipocitoquina con múltiples funciones protectoras. Acta Bioquímica clínica latinoamericana. 2008:42:17-33.

Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595-9.

Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941-6.

Dominguez C. Adiponectina: el tejido adiposo más allá de la reserva inerte de energía. Revista mexicana de endocrinología y nutrición. 2007;15:149-55.

Trujillo ME, Scherer PE. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257:167-75.

Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85-9.

Arikan S, Bahceci M, Tuzcu A, Kale E, Gokalp D. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome. Gynecological Endocrinology. 2010;26:161-66.

Arita Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83.

Michalakis KG, Segars JH. The role of adiponectin in reproduction: from polycystic ovary syndrome to assisted reproduction. Fertil Steril. 2010;94:1949-57.

Spranger J, Möhlig M, Wegewitz U, Ristow M, Pfeiffer A, Schill T, et al. Adiponectin is independently associated with insulin sensitivy in women with polycystic ovary syndrome. Clinical Endocrinology. 2004;61:738-46.

Glintborg D, Andersen M, Hagen C, Fr ystyk J, Hulstrøm V, Flyvbjerg A, et al. Evaluation of metabolic risk markers in polycystic ovarysyndrome (PCOS). Adiponectin, ghrelin, leptin and body composition inhirsute PCOS patients and controls. Eur J Endocrinol. 2006;155:337-45.

Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, Sanchón R, Luque-Ramírez M, et al. Adiponectin andresistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod. 2006;21:2257-65.

Mazloomi S, Shafiri F, Hajihosseini R, Kalantari S, Mazloomzadeh S. Association between Hypoadiponectinemia and low serum concentrations of calcium and vitamin D in women with polycystic ovary syndrome. ISRN Endocrinol. 2012: 1-6.

Wickham EP 3rd, Cheang KI, Clore JN, Baillargeon JP, Nestler JE. Total and high-molecular weight adiponectin in women with the polycysticovary syndrome. Metabolism. 2011;60:366-72.

Ducluzeau P, Cousin P, Malvoisin E, Bornet H, Vidal H, Laville M, et al. Glucose-to-Insulin Ratio Rather than Sex Hormone-Binding Globulin and Adiponectin Levels Is the Best Predictor of Insulin Resistance in Nonobese Women with Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2003;88:3626-31.

Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C. Adiponectin Levels in Women with Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2003;88:2619-23

Carmina E, Orio F, Palomba S, Cascella T, Longo R, Colao A, et al. Evidence for altered adipocyte function in polycystic ovary syndrome. European Journal of Endocrinology. 2005;152:389-94

Pinhas-Hamiel O, Sigal S, Pilpel N, Koren I, Boyko V. Adiponectin levels in adolescent girl with polycystic ovary syndrome (PCOS). Clinical endocrinology. 2009;71:823-27.

Dikmen E, Tarkun I, Ozturk F, Arslan B, Canturk Z. Plasma adiponectin and resistin levels in women withpolycystic ovary syndrome: relation to body mass index and insulin resistance. Turk J Med Sci. 2011;41:45-52.

Olszanecka-Glinianowicz M, Kuglin D, Dabkowska-Huc A, Skalba P. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2011;154:51-6.

O’Connor A, Phelan N, Kyaw T, Boran G, Gibney J, Roche HM. High-Molecular-Weight Adiponectin is Selectively Reduced in Women with Polycystic Ovary Syndrome Independent of Body Mass Index and Severity of Insulin Resistance. J Clin Endocrinol Metab. 2010;95:1378-85.

Yasar L, Ekin M, Gedikbasi A, Erturk A.D, Savan K, Ozdemir A, et al. Serum adiponectin levels in high school girls with polycystic ovary syndrome and hyperandrogenism. Journal of Pediatric and Adolescent Gynecology. 2011;24:90-3.

Fux Otta C, Szafryk de Merecían P, Vocos M, Mengual R, Fiol de Cuneo M. Niveles séricos de adiponectina y parámetros metabólicos en diferentes fenotipos del síndrome de ovario poliquístico. VIII Congreso FASEN. Revista Argentina de Endocrinología y Metabolismo. 2010;47:98.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar H, Futterweit W, et al. Position statement: Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. The Journal of Clinical Endocrinology & Metabolism. 2006;91:4237-45.

Guastella E, Longo R, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010;6:2197- 2201.

Zawadski J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. En: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992. p. 377-84.

Merino P, Schulin-Zuthen C, Codner E. Diagnóstico del síndrome de ovario poliquístico; nuevos fenotipos, nuevas incógnitas. Rev Med Chile. 2009;137:1071-80.

Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2009;15:297-307.


comments powered by Disqus

Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM




Copyright (c) 2015 Revista Colombiana de Obstetricia y Ginecología

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

ISSN Impreso       0034-7434 

ISSN Electrónico   2463-0225

https://doi.org/10.18597/issn.0034-7434